# A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

> **NCT02156076** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 158 (actual)

## Conditions studied

- Paroxysmal Atrial Fibrillation

## Interventions

- **DRUG:** BMS-919373
- **DRUG:** Placebo (Matching with BMS-919373)

## Key facts

- **NCT ID:** NCT02156076
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-25
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-06-01
- **Target enrollment:** 158 (ACTUAL)
- **Why stopped:** Sponsor decision based on business reasons, unrelated to safety
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156076, "A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02156076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*